EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial–Mesenchymal Transition and the PI3K Signalling Pathway

JingRong Miao, PanFeng Feng iD

Journal of Cellular and Molecular Medicine · 2026-04 · 30 (8)

DOI: 10.1111/jcmm.71128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 16.04.2026. Verfasst von JingRong Miao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Procurement Management, Nantong First People's Hospital, Nantong, Jiangsu Province, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Epithelial-Mesenchymal Transition, Signal Transduction, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Pharmaceutical Association-Yaoyanxinsheng Fund, Jiangsu Pharmaceutical Association-Tianqing Fund, Scientific Research Project of Nantong Municipal Health and Family Planning Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastasis remains a critical factor contributing to the low survival rates in colorectal cancer. The pathways through which cycloastragenol suppresses colorectal cancer metastasis are poorly defined. This research directly investigates its anti‐metastatic mechanisms. The anti‐proliferative effects of cycloastragenol were assessed using CCK‐8 assays, while its impact on migration, invasion and apoptosis was evaluated via Transwell assays and flow cytometry. Analysis of protein expression was performed using Western blotting and immunofluorescence. Network pharmacology and molecular docking were employed to predict potential signalling pathways and binding interactions. Additionally, the establishment of an in vivo xenograft mice model enabled us to further validate the antitumour efficacy and mechanistic role of cycloastragenol. Cycloastragenol exhibited a dose‐ and time‐dependent suppression of colorectal cancer cell proliferation. Meanwhile, it inhibits proliferation and migration and promotes apoptosis in a concentration‐dependent manner. Cycloastragenol suppresses the activation of the EMT process. Based on an integrated network pharmacology and molecular docking approach, the PI3K/Akt signalling axis emerged as the foremost candidate mechanism. Cycloastragenol exhibits strong binding affinities with PI3K (interaction sites: ARG4, LYS720) and AKT (interaction sites: TYR18, LEU295), with binding energies of −9.0 kcal/mol and −9.3 kcal/mol, respectively. A marked suppression of tumour growth and metastasis was observed in xenograft models following cycloastragenol treatment. The antitumour efficacy of cycloastragenol is mediated primarily through the suppression of the PI3K/AKT signalling pathway, thereby suppressing EMT and impeding CRC progression. These findings provide a preclinical foundation for the potential clinical application of cycloastragenol in CRC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsEpithelial-Mesenchymal TransitionSignal TransductionPhosphatidylinositol 3-KinasesHumansAnimalsCell MovementCell ProliferationMiceApoptosisMolecular Docking SimulationXenograft Model Antitumor AssaysCell Line, TumorProto-Oncogene Proteins c-aktNeoplasm MetastasisMice, Nude

Stichwörter der Autor:innen

PI3K‐AKT signalling axiscolorectal cancercycloastragenolepithelial‐to‐mesenchymal transitionmolecular docking

Substanzen

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Department of Procurement Management, Nantong First People's Hospital, Nantong, Jiangsu Province, China.
  • Department of Pharmacy, Nantong First People's Hospital, Nantong, Jiangsu Province, China.
  • Nantong Key Laboratory of Innovative Research on Rheumatology and Immunology, Nantong, Jiangsu Province, China.
  • Nantong Clinical Medical College of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu Province, China.

ORCID-Profile: PanFeng Feng

Förderung

  • Jiangsu Pharmaceutical Association-Yaoyanxinsheng Fund
  • Jiangsu Pharmaceutical Association-Tianqing Fund
  • Scientific Research Project of Nantong Municipal Health and Family Planning Commission
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy fund
  • Nantong Pharmaceutical Association Fund
  • Guangzhou Zhiyi Charity Foundation fund
  • Nantong Science and Technology Program Project
  • Fund of drug policy and pharmaceutical care of Nantong City

Zitieren

APA

Miao, J., & Feng, P. (2026). Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial–Mesenchymal Transition and the PI3K Signalling Pathway. Journal of Cellular and Molecular Medicine, 30(8). https://doi.org/10.1111/jcmm.71128

Vancouver

Miao J, Feng P. Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial–Mesenchymal Transition and the PI3K Signalling Pathway. Journal of Cellular and Molecular Medicine. 2026;30(8). doi:10.1111/jcmm.71128

BibTeX
@article{Miao2026,
  author = {Miao, JingRong and Feng, PanFeng},
  title = {Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial–Mesenchymal Transition and the PI3K Signalling Pathway},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {8},
  doi = {10.1111/jcmm.71128}
}
Kostenlos starten →